Cargando…
Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study
CONTEXT: Cyproterone acetate (CPA) is a competitive inhibitor of the androgen receptor and exerts negative hypothalamic feedback. It is often used in combination with estrogens in trans women to achieve feminization. However, CPA has been associated with side effects such as changes in liver enzyme...
Autores principales: | Kuijpers, Suzanne M E, Wiepjes, Chantal M, Conemans, Elfi B, Fisher, Alessandra D, T’Sjoen, Guy, den Heijer, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571811/ https://www.ncbi.nlm.nih.gov/pubmed/34125226 http://dx.doi.org/10.1210/clinem/dgab427 |
Ejemplares similares
-
Response to Letter to the Editor From Laidlaw: “Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-term Follow-up Study on Prevalence, Determinants, and Exposure Years”
por: Madsen, Milou C, et al.
Publicado: (2021) -
The ENIGI (European Network for the Investigation of Gender Incongruence) Study: Overview of Acquired Endocrine Knowledge and Future Perspectives
por: Cocchetti, Carlotta, et al.
Publicado: (2022) -
SAT-745 Lower Serum Estradiol Levels in Assigned Female at Birth Transgender People with Initiation of Testosterone Therapy: Results from the European Network for the Investigation of Gender Incongruence (ENIGI)
por: Defreyne, Justine, et al.
Publicado: (2020) -
Change in Visceral Fat and Total Body Fat and the Effect on Cardiometabolic Risk Factors During Transgender Hormone Therapy
por: Klaver, Maartje, et al.
Publicado: (2021) -
The Role of Estrone in Feminizing Hormone Treatment
por: Tebbens, Marieke, et al.
Publicado: (2021)